Issue link: https://www.e-digitaleditions.com/i/1543258
24 February 2026 Inhalation Quantitative nasal cast services Successful nasal drug delivery depends on knowing where droplets are deposited—not just how they exit the device. Proveris Laboratories Nasal Cast Services measure regional deposition (e.g., vestibule, turbi- nates, nasopharynx) under nasal inhalation flow and head-pose conditions, while automated actuation data reflects true pump use. is integrated approach links formulation rheology and device spray characteristics to actual regional delivery. Clients are leveraging this service and our OINDP expertise to streamline nasal product development. Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proveris.com Respiratory drug product development software Fusion Process Development (FPD) for respiratory drug product R&D is the perfect companion mod- ule to Fusion Inhaler Testing (FIT) for QC. FPD has automated Design of Experiments (DoE) and data modeling for formulation and process R&D. FPD enables you to create companion testing designs for your formulation and device design studies with full bi-directional Chromatography Data Software (CDS) testing automation. Automated CDS testing and data retrieval includes handling of complex data from cas- cade impaction testing and dissolution testing. And FPD operates under full regulatory compliance to maintain data integrity. S-Matrix ® US: +1 707 441-0406 sales@smatrix.com www.smatrix.com Smart, breath-actuated mesh nebulizer HCmed is a CDMO specializing in inhalation drug delivery systems. With proprietary vibrating mesh technology, the company offers an integrated platform for developing and manufacturing drug–device com- bination products. Its FDA 510(k)-cleared AdheResp breath-actuated mesh nebulizer features built-in con- nectivity and supports large-scale production for clini- cal use. Designed to enhance aerosol performance and minimize emissions, AdheResp reflects HCmed's com- mitment to advancing inhaled therapeutics. HCmed will also host RespireX, a Pitch Day event for start- ups and biotechs developing respiratory medicines, on March 11, 2026, in Cambridge, UK, with Chiesi as an Innovation Partner. www.respire-x.events. HCmed Innovations Co., Ltd. Taiwan: +886 2 2732 6596 Chris.vernall@hcmed-inno.com www.hcmed-inno.com